10 CDMO Up & Comers 2026
As one notable company exits the field, growing CDMOs open facilities and secure major contracts. The companies are listed here for making headlines with facility openings, major contracts, and other significant actions, though not yet large enough to crack the A-List Top 10 CDMOs. The post 10 CDMO Up & Comers 2026 appeared first on GEN - Genetic Engineering and Biotechnology News .
1. Artis BioSolutions has combined its U.S. and European capabilities by rebranding as Artis BioSolutions. It acquired Landmark Bio in Watertown, MA and Syngoi in Bilbao, Spain, creating a transatlantic platform for synthetic DNA production and advanced therapy development. 2. AsymBio raised RMB 1.2397 billion ($184 million) in investment from Asymchem Group, Hillhouse Qirui, and others.
The infusion will increase Asymchem's stake to 83.4965%. The company generated over RMB 140 million ($21 million) in first-quarter revenue and RMB 470 million ($70 million) in total revenue in 2025. 3. Bora Group completed an acquisition of MacroGenics' GMP manufacturing operations and CDMO business in Rockville, MD and Frederick, MD.
The price was up to $127.5 million plus potential future customer orders. Bora signed a $250 million five-year contract with GlaxoSmithKline to expand their manufacturing partnership, allowing access to multiple sites within Bora's network. 4. Curia Global is finalizing a recapitalization transaction led by Apollo-affiliated funds.
The deal aims to strengthen the company's financial foundation and long-term success. Curia completed a $4 million upgrade to its aseptic suites in Valladolid, Spain, transitioning to a fully closed system to improve process and product integrity. 5. Gland Pharma signed a technology transfer, manufacturing, and supply agreement with a leading global pharmaceutical company for sterile injectable products.
The portfolio includes oncology and non-oncology products, with an estimated annualized revenue potential of $90 million–$100 million across three sites. Gland also launched a partnership with Neuland Laboratories to establish a dedicated sterile API manufacturing suite at its Visakhapatnam, India facility, adding roughly 1,400 kg (3,086 pounds) of annual production capacity.
6. Neuland Laboratories is completing a $20 million dedicated process development laboratory and integrated kilo lab in Hyderabad, India. The 135,000-square-foot facility will be operational in phases by October, following record revenues of ₹2,000 crore ($215 million) and EBITDA of ₹603.4 crore ($63.4 million) in the fiscal year ending March 31, 2025.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
